pT1N0M0三阴性乳腺癌辅助化疗的长期结局:基于人群队列研究
该研究基于荷兰癌症登记2005–2016年4366例pT1N0M0三阴性乳腺癌患者,评估辅助化疗与长期生存的关系。中位随访8.2年,调整基线特征后化疗与乳腺癌特异性生存改善相关(aHR=0.65,95%CI 0.48–0.89),效应随肿瘤大小而异,pT1c获益最明显,pT1a/pT1b可能不获益甚至有害。
要点
- 辅助化疗与pT1N0M0三阴性乳腺癌更好的BCSS和OS相关。
- 化疗效应随肿瘤大小不同:pT1c显著获益,pT1a可能有害。
- 需结合肿瘤大小个体化决策辅助化疗。
核心结论
- 辅助化疗与pT1N0M0三阴性乳腺癌更好的BCSS和OS相关,但获益主要体现在pT1c肿瘤,pT1a/pT1b可能不抵损害。
研究设计与样本
- 基于荷兰癌症登记2005–2016年诊断为pT1N0M0三阴性乳腺癌的4366例患者的人群队列研究,采用多变量Cox回归和倾向评分加权敏感性分析。
主要发现
- 中位随访8.2年(IQR 5.8–10.9),671例死亡,其中311例死于乳腺癌。
- 调整基线特征后,化疗与BCSS改善相关(aHR=0.65;95%CI 0.48–0.89)。
- 化疗效应随肿瘤大小不同:pT1a aHR=4.28(95%CI 1.12–16.44),pT1b aHR=1.12(95%CI 0.51–2.49),pT1c aHR=0.60(95%CI 0.43–0.82),交互P=0.02。
- OS结果与BCSS一致,倾向评分加权分析证实主要分析结果。
关键数值与推荐
- 共纳入4366例:pT1a 284例,pT1b 923例,pT1c 3159例;53%接受辅助化疗。
- 接受化疗者基线特征更不利:更年轻、肿瘤更大、分级更高。
临床怎么用
- 对于pT1cN0M0三阴性乳腺癌,辅助化疗与显著生存获益相关,可考虑推荐。
- 对于pT1a/pT1bN0M0三阴性乳腺癌,辅助化疗的获益不明确且可能有害,需谨慎个体化决策。
局限性
- 为观察性队列研究,存在残余混杂可能,尽管采用了多变量调整和倾向评分加权。
- 缺乏随机试验数据,化疗决策非随机分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recommendations on adjuvant chemotherapy in pT1N0M0 triple-negative breast cancer (TNBC) differ among international guidelines owing to lack of randomized trial data. We evaluated associations of adjuvant chemotherapy with a long-term outcome in a population-based cohort of pT1N0M0 TNBC. METHODS: All patients diagnosed with pT1N0M0 TNBC in the Netherlands between 2005 and 2016 were identified from the Netherlands Cancer Registry. Patient, tumour and treatment characteristics were recorded. The date and cause of death were obtained from Statistics Netherlands. We used multivariable Cox regression models to evaluate associations of adjuvant chemotherapy with breast cancer-specific survival (BCSS) and overall survival (OS), adjusted for baseline characteristics and performed sensitivity analyses using propensity score (PS) weighting. RESULTS: We identified 4366 patients: 284 with pT1a, 923 with pT1b and 3159 with pT1c tumours. Adjuvant chemotherapy was administered in 53% of patients. Patients receiving chemotherapy had more unfavourable baseline characteristics including younger age, larger tumours and higher tumour grade. At 8.2 years median follow-up (interquartile range = 5.8-10.9), 671 patients had died, of whom 311 because of breast cancer. After adjustment for baseline characteristics, chemotherapy was associated with improved BCSS (adjusted hazard ratio [aHR] = 0.65; 95% confidence interval [CI] = 0.48-0.89). The effect of chemotherapy differed by tumour size (pT1a: aHR = 4.28, 95% CI = 1.12-16.44; pT1b: aHR = 1.12, 95% CI = 0.51-2.49; pT1c: aHR = 0.60, 95% CI = 0.43-0.82; pinteraction = 0.02). Findings for OS were in line with BCSS results. PS-weighting analysis confirmed the results of the primary analysis. CONCLUSIONS: Adjuvant chemotherapy is associated with better BCSS and OS in pT1N0M0 TNBC. Better outcome is most evident in pT1c tumours and may not outweigh harm in pT1a/pT1b tumours.
引用
- Steenbruggen TG, van Werkhoven E, van Ramshorst MS, et al. Adjuvant chemotherapy in small node-negative triple-negative breast cancer. Eur J Cancer. 2020. PMID: 32554215. doi:10.1016/j.ejca.2020.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。